Home » Stocks » Iterum Therapeutics

Iterum Therapeutics PLC (ITRM)

Stock Price: $0.514 USD -0.012 (-2.19%)
Updated Oct 26, 2020 1:16 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 10.91M
Revenue (ttm) n/a
Net Income (ttm) -83.53M
Shares Out 21.24M
EPS (ttm) -5.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $0.514
Previous Close $0.525
Change ($) -0.012
Change (%) -2.19%
Day's Open 0.520
Day's Range 0.503 - 0.530
Day's Volume 3,810,719
52-Week Range 0.501 - 7.190

More Stats

Market Cap 10.91M
Enterprise Value 37.34M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 21.24M
Float 13.87M
EPS (basic) -5.61
EPS (diluted) -5.57
FCF / Share -5.54
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 182,281
Short Ratio 0.02
Short % of Float 1.31%
Beta 0.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income -75.32M
Net Income -83.53M
Free Cash Flow -86.51M
Net Cash -26.43M
Net Cash / Share -1.24
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -91.43%
ROE -1,995.15%
ROIC -1,406.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 0
Overweight 0
Hold 3
Underweight 0
Sell 1

Analyst Consensus: Hold

Price Target

(240.60% upside)
Current: $0.514
Target: 1.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-95.74%71.06%--
Gross Profit0.040.870.51-
Operating Income-102-76.56-29.46-13.36
Net Income-103-77.06-29.41-13.46
Shares Outstanding14.528.730.170.02
Earnings Per Share-7.10-8.82-170.84-568.87
Operating Cash Flow-78.89-75.89-30.60-11.30
Capital Expenditures-0.02-0.09-0.81-
Free Cash Flow-78.91-75.98-31.42-11.30
Cash & Equivalents4.8384.5839.2224.81
Total Debt13.4314.10--
Net Cash / Debt-8.5970.4839.2224.81
Book Value-26.2471.6239.4922.67
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Iterum Therapeutics PLC
Country Ireland
Employees 44
CEO Corey N. Fishman

Stock Information

Ticker Symbol ITRM
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ITRM
IPO Date May 25, 2018


Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was founded in 2015 and is headquartered in Dublin, Ireland.